Protalix BioTherapeutics (PLX) Other Operating Expenses (2011 - 2026)

Protalix BioTherapeutics' Other Operating Expenses history runs 12 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 1778.33% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$18.8 million (down 408.96% YoY), while the FY2025 annual figure was -$11.7 million, down 34.19% from the prior year.
• Other Operating Expenses was -$7.6 million for Q1 2026 at Protalix BioTherapeutics, down from -$6.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $1.4 million in Q3 2024 to a low of -$7.6 million in Q1 2026.
• Historically, Other Operating Expenses has averaged -$2.8 million across 3 years, with a median of -$2.3 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses slipped 24.45% in 2025, then tumbled 1778.33% in 2026.
• A 3-year view of Other Operating Expenses shows it stood at -$5.6 million in 2024, then retreated by 24.45% to -$6.9 million in 2025, then declined by 10.23% to -$7.6 million in 2026.
• The last three Other Operating Expenses figures came in at -$7.6 million (Q1 2026), -$6.9 million (Q4 2025), and $22000.0 (Q3 2025), per Business Quant data.